All News
Dr Bilgin presents on PLEX in AAV. I'm not a believer post-PEXIVAS despite attempts to slice and dice that data and this seems to show no evidence to change my mind @RheumNow #EULAR2021 Abstr#POS0255 https://t.co/U3zwt619lc
Richard Conway RichardPAConway ( View Tweet)
#POS0221 retrospective propensity score corrected observational study TOFA (n:156) vs. BARI (n:138): week 24: CDAI REM (see pic) BARI>TOFA. Factors of treatment resistence in TOFA: OR: Nr of prior bDMARD 1.77 & HAQ-DI 18.6
No such factors in BARI identified.
#EULAR2021 @RheumNow https://t.co/u9Nati2ZJO
Paul Studenic Stiddyo ( View Tweet)
Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021
On day 2 of EULAR , Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab.
https://t.co/r4aNG7KR5h https://t.co/nppgRytnlr
Dr. John Cush RheumNow ( View Tweet)
➡️Percentage achieving PASI75 (not H2H comparison):
⭐️GUS > IXE > INF > SEC > UST > GOL 100mg >ADA> CTZ > TOFA> GOL 50 mg > ETN > APR
⭐️Amongst TNFi (not H2H): INF > GOL > ADA > CTZ > ETN
Great talk by Dr. L Coates on personalized tx approach for PsA.
#EULAR2021 @RheumNow https://t.co/jMGaBlg3Iy
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
➡️%age achieving ACR20 (not H2H comparisons):
⭐️GUS > IXE > TOFA > CTZ > ETN > INF > ADA > SEC > GOL > UST > APR
➡️ Choosing therapies in AxSpA:
⭐️TNFi (ADA), IL17i (SEC), Jaki (UPA); however, axPsA may be different than AxSpA. Need more trials to assess!
#EULAR2021 @RheumNow https://t.co/toMyS3uPAZ
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
How to choose therapy for psoriatic dz?
➡️Should be a personalized approach based on co-morbidities
➡️Below drugs are approved for primary therapy of co-morbid condition:
⭐️IBD: SSZ, ADA, INF. GOL for UC, UST for Crohn's
⭐️Uveitis: GCs & INF preferred, ADA
#EULAR2021 @RheumNow https://t.co/inN07QP9t4
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Step-wise vs rapid escalator approach for PsO & PsA?
⭐️CONTROL study:
➡️bDMARD-naive active PsA w/ IR to MTX for at least 4w randomized to ADA+MTX vs escalated MTX (avg dose 21.8 mg/wk, 55% PO, 36% SQ)
➡️41.5% MDA at wk 16 w/ ADA+MTX vs 13.1%
#EULAR2021 @RheumNow https://t.co/uw5BFQGqNV
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
❗️Dismal trend in #scleroderma survival ➡️38 y data from @Olmstedcounty
An URGENT call for better therapeutics
👉 2.5 fold>general population
👉 NO trend for improved survival
👉 Age, Smoking, Digital Ischemia, ILD and PAH
Check out 👉POS0838 #EULAR2021 #CaitrinCoffey https://t.co/KDStYRI6nz
Ashima Makol MD AshimaMakol ( View Tweet)
Osteoarthritis related bio markers associated with MRI imaging biomarkers
⭐️COMP and MMP-3 negatively associated with knee cartilage thickness
⭐️serum biomarkers could predict future MRI based markers
Abs#POS0129
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
If a patient w/ PsA has high disease activity, would you take the rapid escalator approach (bDMARD) or a step-wise approach (csDMARD to start & escalate per response)?
Be sure to check out Dr. L Coates great talk on personalized tx approach! #EULAR2021 @RheumNow @ElaineHusniMD
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Can biologics change our gut microbiome?
TNFi in IBD related SpA study
⭐️⬇️proteobacteria, ⬆️lachnospiraceae
⭐️TNFi could restore intestinal eubiosis
Abs#POS0230
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Can we act on modifiable predictors of PsA?
⭐️Higher BMI associated with PsA progression from PsO
⭐️family history of PsA, nail pitting predicted PsA development
Abs#POS0145
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
How to Watch EULAR 2021 with Dr. Jack Cush
Listen to RheumNow editor Dr. Jack Cush talk about how to take in all the amazing EULAR 2021 content and information this week. #EULAR2021
https://t.co/cXwUO7J9YS https://t.co/JAieLdAnyb
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 – Day 2 Report
During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. Read our highlights.
https://t.co/NbBqPbbiUy https://t.co/1m6R9F7XWf
Links:
Dr. John Cush RheumNow ( View Tweet)
Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021
On day 2 of EULAR , Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab.
https://t.co/r4aNG7KR5h https://t.co/nppgRytnlr
Links:
Dr. John Cush RheumNow ( View Tweet)
HOT🔥: thermography of hands in IA remotely collected via smartphone correlates w/ US features 0.48, p<0.01 and SJC 0.48, p<0.01), DAS28 (0.73, p<0.01), CDAI (0.84, p<0.01) and SDAI (0.82, p<0.01). A future tool for patients remote follow-up?
#OP0300 @Rheumnow #EULAR2021 https://t.co/MJLpz6eqIy
Aurelie Najm AurelieRheumo ( View Tweet)
Just a reminder: RA-ILD doesn't just happen in early disease; risk continues on long after diagnosis.
PS don't smoke if you have RA; smokers have an adj HR 1.92
PPS don't smoke if you don't want to get RA
PPPS don't smoke.
@MayoClinic POS0210 #EULAR2021 @RheumNow https://t.co/elhvJrK7B4
David Liew drdavidliew ( View Tweet)
Presenting now at #EULAR2021
#COVID19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with #rituximab: a cohort study
https://t.co/QTGkiMcC2d https://t.co/DJB6GooPuJ
Links:
The Lancet Rheumatology TheLancetRheum ( View Tweet)
#EULAR2021. OP0293: Best disease activity measure for SLE flares?
⭐️c-SFI and SLE-DAS had best performance
⭐️SLE-DAS: easy to use for daily practice
@RheumNow https://t.co/9LJfbYxqOs
Eric Dein ejdein1 ( View Tweet)
Which RA pts have high HAQ? F/U of 2 ERA cohorts [NOAR 1001 pts, #ESPOIR 767 pts] compared pts with high vs lower HAQ. DAS28 was = in 2 groups! But high HAQ occurred in older, females &⬆️fatigue OP0183 #EULAR2021 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)